Celcuity, Inc. (NASDAQ:CELC) Given Consensus Rating of “Moderate Buy” by Analysts

Celcuity, Inc. (NASDAQ:CELC) has received a consensus recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and eleven have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $152.0909.

Several research firms have commented on CELC. Macquarie Infrastructure set a $160.00 price objective on shares of Celcuity in a report on Thursday, May 28th. Craig Hallum dropped their price objective on shares of Celcuity from $189.00 to $171.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Wells Fargo & Company dropped their price objective on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a report on Wednesday, June 3rd. Guggenheim reaffirmed a “buy” rating on shares of Celcuity in a report on Wednesday, June 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $157.00 price objective on shares of Celcuity in a report on Friday, May 15th.

Insider Transactions at Celcuity

In other news, Director David Dalvey sold 25,000 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.68, for a total value of $3,517,000.00. Following the sale, the director directly owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. This represents a 27.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the transaction, the director owned 6,760 shares in the company, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 37,000 shares of company stock worth $5,111,950. Insiders own 13.33% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Creative Planning bought a new position in Celcuity during the second quarter valued at approximately $177,000. Rhumbline Advisers grew its position in Celcuity by 1.2% during the second quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock valued at $570,000 after acquiring an additional 503 shares during the last quarter. XTX Topco Ltd bought a new position in Celcuity during the second quarter valued at approximately $169,000. Quantinno Capital Management LP grew its position in Celcuity by 20.7% during the second quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock valued at $3,245,000 after acquiring an additional 41,756 shares during the last quarter. Finally, Paloma Partners Management Co grew its position in Celcuity by 285.8% during the second quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock valued at $1,097,000 after acquiring an additional 60,849 shares during the last quarter. 63.33% of the stock is currently owned by institutional investors.

Celcuity Price Performance

Shares of NASDAQ:CELC opened at $90.21 on Wednesday. The company’s 50-day moving average is $115.92 and its 200 day moving average is $110.75. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. The company has a market capitalization of $4.40 billion, a P/E ratio of -23.13 and a beta of 0.10. Celcuity has a fifty-two week low of $11.27 and a fifty-two week high of $151.02.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. On average, equities research analysts forecast that Celcuity will post -3.69 earnings per share for the current year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.